Atnm julyconference
Upcoming SlideShare
Loading in...5
×
 

Atnm julyconference

on

  • 87 views

 

Statistics

Views

Total Views
87
Views on SlideShare
87
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Atnm julyconference Atnm julyconference Presentation Transcript

  • Actinium Pharmaceuticals, Inc. This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. July 2014 Company Presentation Ticker: ATNM (NYSE MKT)
  • 2 Disclaimer and Safe Harbor Statement Disclaimer The contents of this presentation and the information which you are given at the time of these slides and the presentation have not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation and its slides for the purpose of engaging in investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. These slides and the presentation are exempt from the general restriction (in section 21 of the Act) on the communication of invitations or inducements to engage in investment activity on the grounds that it is made to: (a) persons who have professional experience in matters relating to investments who fall within Article 19(1) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (b) high net worth entities and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(1) of the Order (all such persons together being referred to as “relevant persons”). Any person who is not a relevant person should not rely on this presentation or any of its contents and all persons (whether relevant persons or otherwise) are recommended to seek their own independent financial advice from a person authorized for the purposes of the Act before engaging in any investment activity involving the Company’s securities. Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995. Such forward-looking information and statements are based on the current estimates and projections of the Company or assumptions based on information currently available to the Company. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of revenues, future national or regional economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward- looking information contained in this presentation. Any forward-looking statements or information in this presentation speak only as at the date of this presentation.
  • 3 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Company Description ACTINIUM is an oncology focused company with proprietary alpha and beta emitter (radiation) technology initially targeting early and late stage leukemia. We are one of only three companies in the world developing alpha emitters.
  • 4 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Company Overview ♦ Overall investment of $100M to develop Alpha Emitter Technology to treat Leukemia ♦ 35 Patents (owned and in-licensed from Memorial Sloan- Kettering Cancer Center and others) ♦ Advisory Board Represents all Major Cancer Centers including Memorial Sloan-Kettering, Fred Hutchinson and MD Anderson ♦ Iomab-B on the cusp of entering Phase III for Relapsed and Refractory Acute Myeloid Leukemia (AML) (Patients > 55)
  • 5 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Company Overview (continued) ♦ Actimab-A in Phase I/II Trials for Newly Diagnosed AML ♦ 1 of only 3 Companies in World with Alpha Technology ♦ Fully Funded through Late 2015 ♦ World Class Board of Directors ♦ Sloan-Kettering Largest Shareholder and also Merck a Shareholder
  • 6 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Financial Facts Actinium Pharmaceuticals Stock Ticker ATNM Stock Exchange NYSE MKT Market Cap 188.4M Average 3 Month Volume 134,406 Shares Outstanding 27.4M (40.0M fully diluted) Float 21.1M Cash as of Mar 31, 2014 5.9M Cash from Financing 13.7M
  • 7 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Cancer Treatment Options Treatment % 50% <10% Pharmaceutical Revenue % <3% ~30% Always a pharmaceutical Strong IP protection Mostly proprietary Monoclonal Antibodies (mAbs)Radiation External radiation majority treatment Internal radiation has mostly no IP Commoditized ♦ ♦ ♦ ♦ ♦ ♦ Antibody Approaches Targeting Cancer Cells α Cancer cell β Range .06mm Range 1 - 10mm DNA
  • 8 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. ATNM’s Proprietary Technology Platform ♦ Delivers radiation to cancer site via pharmaceutical carrier through an injection – Antibody provides precision, targeting cancer cells specifically while avoiding normal cells – α emitters provide killing power with a very short range for narrow targeting – β emitters kill by crossfire which is useful in select indications * APIT is Actinium Pharmaceutical’s Alpha Particle Immunotherapy platform technology. It does not apply to Iomab-B. ** Certain β emitters, specifically iodine 131 in Iomab-B, do not require a linker. APIT* Technology Antibody (targeting agent) Chelator (linker) α / β** emitter (killing agent)
  • 9 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Clinically Relevant  Emitters * Clinically relevant but commercially not feasible in ATNM’s opinion. * * Acquired by Bayer for this amount. α emitter Platform Potential Half Life Stage IP Ownership Market Cap ($mm) Actinium 225 Yes 10 days Phase I/II Actinium Pharmaceuticals Bismuth 213 Yes 46 minutes Phase II Actinium Pharmaceuticals Radium 223 No 11 days Marketed Algeta Thorium 227 Yes 18 days Preclinical Algeta Astatine 211 * Yes 7 hours Phase II Duke University NM Lead 212 * Yes 11 hours Phase I Areva Med NM Bismuth 212 * Yes 1 hour Preclinical NM NM $141 $1,601 $ 188 $2,900**
  • 10 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Robust Intellectual Property Protection * DOTA is the name of the chelator (linker) that Actinium uses to attach the antibody to the α emitter. Area Description US Expiration US Status Owner/Licensor Platform Technology Metastases larger than 1 mm 2019 Issued MSKCC Platform Technology Antibody conjugates with DOTA chelators; methods of treating cancer using the same 2021 Issued MSKCC Drug preparation methods Actinium 225 labeling method 2030 Pending Owned Drug preparation methods Bismuth 213 labeling method 2019 Issued MSKCC Isotope production methods Actinium 225 manufacturing in a cyclotron 2026/2027 Issued Owned Monoclonal antibody composition and production Manufacturing of leukemia targeting antibody 2014 Issued Abbott Laboratories
  • 11 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. ATNM’s Product Pipeline s.d. – single dose f.d. – fractionated dose (2) 1 HSCT stands for Hematopoietic Stem Cell Transplantation, a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient. 2 ATNM has decided to discontinue development of Bismab-A at this time due to supply, logistics and cost reasons. Actimab-A is the second generation drug of Bismab-A. 3 Properties of actinium 225 are uniquely suited for Antiangiogenesis and ATNM is considering options for further development in that area. 4 Glioblastoma (GBM) and breast cancer models are founded on an antiangiogenesis approach. Antiangiogenesis therapies starve cancerous tumors by choking off blood supplies to them.
  • 12 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Iomab-B: Next Step – Phase III Trial ♦ Experience with 250+ patients in 5 Phase I and II clinical trials ♦ In-licensed from Fred Hutchinson Cancer Center, 7 ongoing physician trials with BC8 mAb ♦ Indication is to condition bone marrow in relapsed and refractory AML patients over 55 years old in preparation for HSCT Iomab-B regimen Conventional Care (high dose chemo followed by HSCT) ♦ Almost all patients eligible ♦ <10% eligible ♦ ~30% survive 1 year plus, ~20% survive 2 years plus ♦ <10% survive 1 year plus, <2% survive 2 years plus ♦ Up to $200K per patient ♦ Up to $330K per patient Treatment Options for Older Refractory AML Patients* Survival: Cost: Treatment: Usage: *Source: Oran B, and Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012;97(12):1916- 1924. doi:10.3324/haematol.2012.066100 “Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of the disease”, Dalia Mahmoud, MBA, Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc and Marja Hensen, MSc, 54th ASH Annual Meeting abstract.
  • 13 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Iomab-B Phase I/II Results ♦ Only potential cure for blood cancers is HSCT, but vast majority of patients over 50 are ineligible – Iomab-B has demonstrated ability to successfully prepare these patients for HSCT ♦ Clinical trials completed in 250+ patients with various incurable blood cancers – In both PI and PII trials, Iomab-B led to effective treatment in patients with no other options left All relapsed/refractory AML patients over 50 Rel/ref AML patients over 50 w/ poor cytogenetics 30% 19% 10% 0% 10% 0% 0% 5% 10% 15% 20% 25% 30% 35% 1 year 2 years PercentageSurvival Iomab-B HSCT (N=27) Current HSCT (N=10) Chemotherapy (N=61) 33% 16% 3% 0% 3% 0% 0% 5% 10% 15% 20% 25% 30% 35% 1 year 2 years PercentageSurvival Iomab-B HSCT (N=18) Current HSCT (N=19) Chemotherapy (N=95) N = Number of patients treated; Iomab-B results from FHCRC clinical trials; Current HSCT and Chemotherapy results from MD Anderson outcomes analysis.
  • 14 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Iomab-B FDA Meeting Results ♦ A successful End of Phase II meeting was held with the FDA and agreements were reached on the following – Path to approval – Number of studies – Phase III trial design to support a BLA submission – Patient population – Study size (n) – Primary and secondary endpoints – Statistical considerations
  • 15 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Currently no approved treatments for Iomab-B targeted patients Phase I and Phase II represent physician trials at Fred Hutchison Cancer Research Center. Phase III trials represent ATNM sponsorship. Non-AML timelines are projections and the Company makes no representation as to their ability to meet these timelines. Sources: “Current Uses and Outcomes of Hematopoetic Stem Cell Transplantation 2010”, CIMBTR Summary Slides; “Trade, foreign policy, diplomacy and health: Pharmaceutical Industry”, WHO website, http://www.who.int/trade/glossry/story073/en/ ; “Hematopoetic stem cell transplantation A Global Perspective”, NIH Public Access, JAMA 2010; Company Estimates Iomab-B Development Plan Indication* 2014 2015 2016 2017 2018 2019 2020 2021 2022 WW Mkt. potential Acute Myeloid Leukemia $ 793 Myelodysplastic Syndrome $ 264 Acute Lymphoblastic Leukemia $ 264 Non-Hodgkins Lymphoma and Hodgkins disease $ 1,455 Multiple Myeloma $ 1,322 Total $ 4,098 III Sales start III Sales startIII Sales startII III III Sales startII Approval Approval Approval III Sales startIII Approval Approval
  • 16 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Actimab-A vs. Current Treatments Treatment: Usage: ♦ 64% of patients 60+ use this option due to lack of tolerable alternatives ♦ 36% of patients 60+ are eligible ♦ Potentially any AML patient due to limited side effects Survival: ♦ Less than 2 months ♦ Less than 6 months ♦ Limited history; Bismab-A trials show median survival is 4x greater Cost: ♦ $55K per patient ♦ $170K per patient ♦ $60K per patient New Treatment Option Supportive Care Actimab-AHigh Dose Chemotherapy Current Treatment Options* *Source: ARCH INTERN MED/Vol 162, July 22, 2002; Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease, Dalia Mahmoud, MBA, Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc and Marja Hensen, MSc, 54th ASH Annual Meeting.
  • 17 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Target: ♦ AML ♦ AML Effectiveness: ♦ Proof of concept in humans + 500x more potent than Bismab-A Clinical Stage: ♦ Excellent results in Phase II ♦ Currently in a Phase I/II Trial Supply Chain: ♦ Complex, high COGS + Simple, 10x lower COGS Ease of Use: ♦ Complex on site preparation + Central manufacturing ♦ Does not require additional diagnostics ♦ Does not require additional diagnostics Bismab-A Actimab-A Actimab-A shows superior efficacy to Bismab-A in a comparable trial * More than 5% of bone marrow blasts signifies persistent presence of leukemia cells. Bismab-A Profile Actimab-A Advantages 1st Generation 2nd GenerationAPIT Platform Bismab-A experience implies successful Actimab-A trial results Parameter Bismab-A Actimab-A Elimination of peripheral blasts 27% 63% Bone Marrow blasts decrease by 50% or more 28% 50% Bone Marrow blasts 5% or less post treatment* 0% 20%
  • 18 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Actimab-A Clinical Trial Update ♦ Started the new multicenter Phase I/II clinical trial ♦ Expanded the number of participating clinical centers: – Memorial Sloan-Kettering Cancer Center, Johns Hopkins Medicine, Fred Hutchinson Cancer Center, University of Pennsylvania Health Center, MD Anderson Cancer Center ♦ New protocol sets lower standard than MSKCC PI Trial – Treating newly diagnosed patients – Introducing cytoreduction (reduces the number of cancer cells) – New patient population is likely to respond better to treatment based on medically accepted criteria – No toxicity outside of blood cells at doses expected to be clinically effective ♦ Targeting end of Phase II trial in 2015, preliminary data by ASH 2014 ♦ No new AML drugs have been approved; unmet medical needs remain, which should create interest from potential licensors, investors (Stemline, Marshall Edwards)
  • 19 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Market Positioning for Iomab-B, Actimab-A Treatment Response TreatmentsDiagnosis AML Age >55 Complete Response Relapsed & Refractory AML HSCT Death High dose chemotherapy Actimab-A Complete Response Death Reduced Intensity BM Conditioning Reduced Intensity BM Conditioning Iomab-B ♦ HSCT is a procedure that restores stem cells destroyed by high doses of chemotherapy and/or radiation therapy ♦ HSCT is widely used in other forms of cancer outside of AML ♦ ATNM can leverage its proprietary platform for additional HSCT indications Negative Response ATNM Pipeline Drugs Positive Response Current Treatments ATNM products target both treatment stages for AML patients over 55 years of age
  • 20 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Market Potential of Product Pipeline ♦ The $1.3 billion Bone Marrow Transplant (BMT) market in the US is largely unaddressed by novel pharmaceutical drug companies ♦ BMT is the fastest growing hospital procedure in the US – ~20,000 of the ~60,000 BMTs in 2010 were performed in the US ♦ Sustained growth in patients treated over 55 yrs old – 8% in 2000 to 21% in 2005 and 27% in 2007 ♦ Acute Myeloid Leukemia is the deadliest form of leukemia – 55% of AML patients are over 65 years old – Disease is worse in older people – Insufficient treatment options are available in the marketplace – Treatment kills as many patients as it helps due to toxicity HSCT (Iomab-B) AML (Actimab-A) 1. Target market includes USA, EU and Japan 2. Market Potential calculated based on assumption that Actinium products for solid cancer indications will be priced at $20,000 per treatment; HSCT preparation product will be priced at $85,000 per treatment; AML product will be priced at $60,000 per treatment; and GBM product will be priced at $60,000 per treatment. Estimates based on independent third party research and adjusted for lower pricing in non-US markets. # Cancer Indication Cases/Yr. in target market1 Target Population Worldwide Market Potential ($mm)2 1st HSCT (Bone Marrow) 48,000 48,000 $4,100 2nd Acute Myeloid Leukemia (AML) 41,600 24,000 $920 3rd Glioblastoma Multiforme (GBM) 26,500 26,500 $1,100 4th Prostate Cancer (metastatic) 591,000 298,455 $5,959 5th Metastatic Colorectal Cancer 536,000 241,200 $4,824 Source: GLOBOCAN, SEER , and the Company
  • 21 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Recent Phase I/Phase II Cancer Licensing Deals Company Phase at Signing Deal Size Upfront Fee Date Deal Description Algeta Phase II $800 $61 9/3/2009 Algeta signs $800 million deal with Bayer for Alpharadin in prostate cancer bone metastases Areva Med Phase I NA NA 7/27/2012 Areva Med signs agreement with Roche for an alpha radio-immunotherapy platform (Lead- 212) in malignant cancer Endocyte Phase II $1,000 $120 4/16/2012 Endocyte signs agreement with Merck for Vintafolide (EC145) Genmab Phase I/II $1,100 $55 8/30/2012 Genmab signs agreement with Johnson & Johnson for Daratumumab in multiple myeloma Innate Pharma Phase I $465 $35 7/6/2011 Innate Pharma signs agreement with Bristol-Myers Squibb for AML antibody IPH2102 Medivation Phase II $765 $110 10/27/2009 Medivation signs agreement with Astellas Pharma for MDV3100 Threshold Pharmaceuticals Phase II $592 $25 2/3/2012 Threshold Pharmaceuticals signs agreement with Merck KGaA for TH-302 in AML and other indications Topotarget Phase II $350 $30 2/2/2010 TopoTarget signs agreement with Spectrum Pharmaceuticals for Belinostat All Figures in USD ($mm) Rich deals available for novel technologies with proof of concept Source: Medtrack, Company Reports.
  • 22 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Near-term Value Drivers ♦ Iomab-B – Complete PIII Protocol – Start cGMP mAb mfg – Start drug mfg cGMP process – Complete cGMP mAb mfg – Complete Drug mfg cGMP – Submit PIII IND – Start PIII ♦ Actimab-A – Complete PI trial – Complete mfg. improvements – Start and complete PII trial ♦ Third Program – Start preclinical development – Complete preclinical development – File IND Multiple development milestones in next 12-18 months as ATNM’s products advance to a stage of development  Uplisting to NYSE MKT (Accomplished March 26, 2014) ♦ Additional Analyst Coverage ♦ Collaborations
  • 23 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Core Team & Advisors Team Background Kaushik J. Dave, PhD, MBA President and CEO, ♦ 25 years of Pharma and Biotech industry at both big Pharma and small startups. ♦ Formerly, EVP at Antares Pharma Inc., VP at Palatin Technologies Inc., and Big Pharma (Schering-Plough and Merck) ♦ BPharm from University of Bath (UK), PhD from University of Kansas, MBA from Wharton School at The University of Pennsylvania; Gerri Henwood Chief Development Officer ♦ President & Founder of Malvern Consulting Group and President & CEO of Recro Pharma ♦ Former Founder, President & CEO of Auxilium Pharmaceuticals, Inc (NASDAQ:AUXL) ♦ Former Founder & CEO of IBAH (formerly NASDAQ listed; acquired by Omnicare (NYSE)) ♦ Board of Directors of Alkermes, Inc. (NASDAQ:ALKS), Garnet BioTherapeutics, Inc., LZ Therapeutics, Inc., and MAP Pharmaceuticals, Inc.(NASDAQ:MAPP) Dragan Cicic, MD, MBA COO & CMO ♦ 9 years at Actinium Pharmaceuticals (ATNM), previously serving as Medical Director ♦ Formerly a strategic consultant at QED Technologies and an investment banker at SG Cowen Securities ♦ MBA, Wharton School at The University of Pennsylvania; MD, School of Medicine at The Belgrade University ♦ Nieman Fellow at Harvard University Richard Steinhart BBA, MBA Director ♦ Industry Consultant ♦ Formerly Senior Vice President, Finance and Chief Financial Officer of MELA Sciences Inc. ♦ Formerly Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies. ♦ B.B.A. and M.B.A., Pace University Sergio Traversa, PharmD, MBA Director ♦ CEO of Relmada Therapeutics, Inc. ♦ 25+ years of management and investment experience in healthcare as a Portfolio Manager & Sr. Pharmaceutical Analyst (Mehta & Isaly, ING Barings, Merlin BioMed & Rx Capital) and in industry (CNS at Eli Lilly, Pfizer) ♦ MBA, Finance at New York University, Laurea of Pharmacy at the University of Turin David Nicholson, PhD Director ♦ Head of R&D, Bayer CropScience ♦ Formerly Sr. VP and Head Worldwide Licensing and Knowledge Management at Merck ♦ Formerly Head of R&D at Organon prior to acquisition by Schering-Plough ♦ Ph.D., University of Wales Sandesh Seth, MS, MBA Chairman of the Board ♦ Head of Healthcare Investment Banking at Laidlaw & Company (UK) Ltd. ♦ 20+ years experience in investment banking (Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in industry (Pfizer, Warner-Lambert, SmithKline) ♦ MBA, Finance at New York University; MS, Pharmaceutical Sciences at University of Oklahoma Health Center
  • 24 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Clinical Advisory Board Treatment Center Advisory Board Members Memorial Sloan Kettering Cancer Center David Scheinberg, M.D., PhD Chairman of Experimental Therapeutics at MSKCC Vincent Astor Chair Scientific Co-Founder Fred Hutchinson Cancer Center Elihu H. Estey, M.D. Professor of Medicine Division of Hematology University of Washington School of Medicine WHO Treatment guidelines for AML John Pagel, M.D., PhD Assistant Professor/Assistant Member Department of Medicine, Division of Oncology Lead Investigator for Iomab-B MD Anderson Cancer Center Hagop Kantarjian, M.D. Professor of Leukemia Department Chair, Department of Leukemia Division of Cancer Medicine University of Texas Key Investigator for Actimab-A Johns Hopkins Medicine Richard Wahl, M.D. Director, Division of Nuclear Medicine/PET Professor of Nuclear Medicine Professor of Radiology and Oncology Vice Chairman, Technology and New Business Development Department of Radiology “Father of PET Imaging” Judith Karp, M.D. Professor of Oncology Director, Adult Leukemia Program, Division of Hematologic Malignancies The Sidney Kimmel Comprehensive Cancer Center Columbia University Medical Center Joseph G. Jurcic, M.D. Professor of Clinical Medicine Director of Hematologic Malignancies Hematology/Oncology Division CAB Chairman, Lead Investigator for Actimab-A trials University of Pennsylvania Health System Alexander Perl, M.D. Assistant Professor of Medicine Division of Hematology/Oncology
  • 25 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. Highlights  Prior clinical data for both Iomab-B and Actimab-A favor successful trial results  Breakthrough therapy potential implies successful market penetration for both Iomab-B and Actimab-A  APIT platform poised to deliver multiple blockbuster cancer drugs  An expert team possessing the vision and desire to enhance shareholder value  Positioned to benefit from increased market recognition of targeted payload therapies and an initial high-value, niche product model
  • Actinium Pharmaceuticals, Inc. This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein. July 2014 Company Presentation Ticker: ATNM (NYSE MKT)